Loading...
Market
Story
Eisai and Biogen Launch Alzheimer's Drug Leqembi in China at USD24,800 per Year
Jun 27, 2024, 11:37 PM
Eisai and Biogen have launched their Alzheimer's treatment Leqembi in China, marking the third country after the United States and Japan to approve the drug. The treatment, which was approved by the Chinese regulator in January, is expected to be put into clinical use in Chinese hospitals, according to a hospital staffer in Shanghai. Leqembi, also known as Lecanemab, will cost CNY180,000 (USD24,800) per one-year cycle. This development signifies a significant step in the availability of advanced Alzheimer's treatments in China.
View original story
Similar markets
High uptake (over 10,000 patients) • 25%
Moderate uptake (5,000-10,000 patients) • 25%
Low uptake (1,000-5,000 patients) • 25%
Very low uptake (under 1,000 patients) • 25%
More than $500 million • 25%
$300 million to $500 million • 25%
$100 million to $300 million • 25%
Less than $100 million • 25%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
Less than 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
More than 3 million • 25%
Yes • 50%
No • 50%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,001 to 300,000 • 25%
More than 300,000 • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
High (>20% of target market) • 25%
Moderate (10%-20% of target market) • 25%
Low (1%-10% of target market) • 25%
Negligible (<1% of target market) • 25%
